Trials / Completed
CompletedNCT00157105
Safety and Efficacy Study of a Recombinant and Protein-Free Factor VIII (rAHF-PFM) in Hemophilia A Patients Undergoing Surgery
Recombinant Antihemophilic Factor (rAHF PFM) Manufactured and Formulated Without Added Human or Animal Proteins: Evaluation of Safety and Efficacy in Hemophilia A Patients Undergoing Surgical or Invasive Procedures
- Status
- Completed
- Phase
- Phase 2 / Phase 3
- Study type
- Interventional
- Enrollment
- 59 (actual)
- Sponsor
- Baxalta now part of Shire · Industry
- Sex
- Male
- Age
- 5 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to evaluate whether rAHF-PFM is safe and effective in the treatment of hemophilia A patients undergoing surgery.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Antihemophilic factor, recombinant, manufactured protein-free |
Timeline
- Start date
- 2001-02-12
- Primary completion
- 2004-08-03
- Completion
- 2004-08-03
- First posted
- 2005-09-12
- Last updated
- 2021-08-24
Locations
10 sites across 1 country: United States
Source: ClinicalTrials.gov record NCT00157105. Inclusion in this directory is not an endorsement.